POSB20 Health Technology Assessment (HTA) of BRAF/MEK Inhibitors in Non-Resectable Metastatic BRAFV600 Melanoma Patients

M Dimitrakopoulou, A Kasselouris,C Kani,K Souliotis,S Markantonis

Value in Health（2022）

引用 0|浏览3

暂无评分

摘要

Today, the orally administered BRAF/MEK inhibitors, Dabrafenib/Trametinib, Encorafenib/Binimetinib and Vemurafenib/Cobimetinib, constitute one of the most frequently prescribed therapeutic regimens for the treatment of non-operable metastatic melanoma with a BRAF-V600 mutation.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要